The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
Open accessAbstract
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled with 5-fold decreased anthracycline toxicity in chemotherapy-refractory patients. Here we report phase II studies using a similar material (FCE28068) in patients with breast (n=17), non-small cell lung (NSCLC, n=29) and colorectal (n=16) cancer. Up to 8 courses of PK1 (280 mg/m(2) doxorubicin-equivalent) were given i.v., together with 123I-labelled imaging analogue. Toxicities were tolerable, with grade 3 neutropenia more prominent in patients with breast cancer (4/17, 23.5% compared with 5/62, 8.1% overall). Of 14 evaluable patients with breast cancer 3 had partial responses (PR), all anthracycline-naïve patients. In 26 evaluable patients with NSCLC, 3 chemotherapy-naïve patients had PR. In contrast, none of the 16 evaluable patients with colorectal cancer responded. Imaging of 16 patients (5 with breast cancer, 6 NSCLC, 5 colorectal cancer) showed obvious tumour accumulation in 2 metastatic breast cancers, although unfortunately no images were obtained from patients who responded. These results show 6/62 PR with limited side effects, supporting the concept that polymer-bound therapeutics can have modified and improved anticancer activities and suggesting the approach should be explored further for breast cancer and NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Saito, G., Swanson, J. A., & Lee, K.-D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00179-5 · Cited by 1,407
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo
Maeda, H., Seymour, L. W., & Miyamoto, Y. (1992) · Bioconjugate Chemistry · doi:10.1021/bc00017a001 · Cited by 560
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., & Gabizon, A. (2000) · Cancer · doi:10.1002/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z · Cited by 385
Passive tumor targeting of soluble macromolecules and drug conjugates.
Seymour, L. W. (1992) · PubMed · Cited by 374
Meerum Terwogt, J. M., ten Bokkel Huinink, W. W., Schellens, J. H., Schot, M., Mandjes, I. A., Zurlo, M. G., Rocchetti, M., Rosing, H., Koopman, F. J., & Beijnen, J. H. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200104000-00003 · Cited by 279
Cited by
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,257
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
The expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767
Qu, J., Zhao, X., Ma, P. X., & Guo, B. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.06.001 · Cited by 593
Polymeric Conjugates for Drug Delivery
Larson, N., & Ghandehari, H. (2012) · Chemistry of Materials · doi:10.1021/cm2031569 · Cited by 580
HPMA copolymers: Origins, early developments, present, and future☆
Kopeček, J., & Kopečková, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.10.004 · Cited by 576
Applications of nanoparticles for diagnosis and therapy of cancer
Baetke, S. C., Lammers, T., & Kiessling, F. (2015) · The British Journal of Radiology · doi:10.1259/bjr.20150207 · Cited by 494
Supramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
Shan, W., Zhu, X., Liu, M., Li, L., Zhong, J., Sun, W., Zhang, Z., & Huang, Y. (2015) · ACS Nano · doi:10.1021/acsnano.5b00028 · Cited by 395
Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies
Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., & Yeo, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300697h · Cited by 382
Polymeric nanostructured materials for biomedical applications
Tang, Z., He, C., Tian, H., Ding, J., Hsiao, B. S., Chu, B., & Chen, X. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.05.005 · Cited by 363
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.005 · Cited by 362
Prodrugs for improving tumor targetability and efficiency
Mahato, R., Tai, W., & Cheng, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.02.002 · Cited by 353
Polymer–drug conjugates: Origins, progress to date and future directions
Kopeček, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.014 · Cited by 347
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications
Rizzo, L. Y., Theek, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.02.020 · Cited by 336
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
Gaspar, R., & Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.003 · Cited by 304
Nanotechnological carriers for cancer chemotherapy: The state of the art
Estanqueiro, M., Amaral, M. H., Conceição, J., & Sousa Lobo, J. M. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.12.041 · Cited by 298
Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy
Avramović, N., Mandić, B., Savić-Radojević, A., & Simić, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040298 · Cited by 296
Liu, M., Zhang, J., Zhu, X., Shan, W., Li, L., Zhong, J., Zhang, Z., & Huang, Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.008 · Cited by 269
Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment.
Wong, C. Y., Al-Salami, H., & Dass, C. R. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.003 · Cited by 257
New opportunities and old challenges in the clinical translation of nanotheranostics
Gawne, P. J., Ferreira, M., Papaluca, M., Grimm, J., & Decuzzi, P. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00581-x · Cited by 255
Polymer therapeutics as nanomedicines: new perspectives
Duncan, R. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.05.507 · Cited by 254
Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.007 · Cited by 252
Nanoparticles for Imaging: top or Flop?
Kiessling, F., Mertens, M. E., Grimm, J., & Lammers, T. (2014) · Radiology · doi:10.1148/radiol.14131520 · Cited by 228
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Ritchie, J. W. A., & Williams, R. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.03.006 · Cited by 7
Metadata
- Authors
- Seymour
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2009-05-07
- Volume
- 34
- Issue
- 6
- Pages
- 1629-36
- ISSN
- 1019-6439 (ISSN-L)
- OpenAlex
- W2148649439
- Cited by
- 304
- References
- 24
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.